Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 11;12(2):591.
doi: 10.3390/jcm12020591.

Accidental Morcellation of Uterine Leiomyosarcoma Influences Relapse Free Survival but Does Not Negatively Influence Overall Survival

Affiliations

Accidental Morcellation of Uterine Leiomyosarcoma Influences Relapse Free Survival but Does Not Negatively Influence Overall Survival

Verena M C Reichert et al. J Clin Med. .

Abstract

Background: Uterine leiomyosarcoma (LMS) is a rare entity amongst malignant gynaecological tumours and is mostly diagnosed after surgery for benign leiomyoma (LM) of the uterus. As minimal invasive surgery is widely used, the morcellation of LM and the uterus is rather common. As there is little known about the impact of the morcellation of LMS on local and distant metastases, as well as overall survival, we carried out a large-scale retrospective study. Methods: A total of 301 LMS cases from the German Clinical Competence Centre for Genital Sarcomas and Mixed Tumours were analysed. We distinguished morcellated and non-morcellated LMS from pT1 and >pT1 tumours. Fine−Gray competing risks regressions and cumulative incidence rates were computed for the time to local recurrence, distant metastases, and patient death. Results: The recurrence free interval in pT1 LMS was significantly lower in the morcellation group with a 2-year cumulative incidence rate of 49% vs. 26% in non-morcellated LMS (p = 0.001). No differences were seen in >pT1 tumours. Distant metastases were more frequently found in non-morcellated pT1 LMS compared to the morcellated cases (5-year cumulative incidence: 54% vs. 29%, p < 0.001). There was no significant difference in time to death between both groups neither in the pT1 stages nor in >pT1 disease. Subdistribution hazard ratios estimated by multivariable competing risks regressions for the morcellation of pT1 LMS were 2.11 for local recurrence (95% CI 1.41−3.16, p < 0.001) and 0.52 for distant metastases (95% CI 0.32−0.84, p = 0.008). Conclusions: Tumour morcellation is not associated with OS for pT1 tumours. The morcellation of pT1 LMS seems to prolong the time to distant metastases whereas local recurrence is more likely to occur after the morcellation of pT1 LMS.

Keywords: leiomyosarcoma; malignancy; morcellement; recurrence; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Cumulative incidence rates of the time to local recurrence (top), distant metastases (middle), and LMS mortality (bottom) are plotted in relation to LMS morcellation at stages pT1 (left panel (a,c,e)) and >pT1 (right panel (b,d,f)). Blue curves showing morcellated, red curves showing non-morcellated LMS with 95% confidence bands, respectively.

References

    1. Khan A.T., Shehmar M., Gupta J.K. Uterine fibroids: Current perspectives. Int. J. Womens Health. 2014;6:95–114. doi: 10.2147/IJWH.S51083. - DOI - PMC - PubMed
    1. Kohler G., Vollmer M., Nath N., Hessler P.A., Dennis K., Lehr A., Koller M., Riechmann C., Bralo H., Trojnarska D., et al. Benign uterine mass-discrimination from leiomyosarcoma by a preoperative risk score: A multicenter cohort study. Arch. Gynecol. Obstet. 2019;300:1719–1727. doi: 10.1007/s00404-019-05344-0. - DOI - PubMed
    1. Lewis T.D., Malik M., Britten J., San Pablo A.M., Catherino W.H. A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma. Biomed. Res. Int. 2018;2018:2414609. doi: 10.1155/2018/2414609. - DOI - PMC - PubMed
    1. Roberts M.E., Aynardi J.T., Chu C.S. Uterine leiomyosarcoma: A review of the literature and update on management options. Gynecol. Oncol. 2018;151:562–572. doi: 10.1016/j.ygyno.2018.09.010. - DOI - PubMed
    1. Skorstad M., Kent A., Lieng M. Uterine leiomyosarcoma—Incidence, treatment, and the impact of morcellation. A nationwide cohort study. Acta Obstet. Gynecol. Scand. 2016;95:984–990. doi: 10.1111/aogs.12930. - DOI - PubMed

LinkOut - more resources